Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
Aditxt Inc. (NASDAQ: ADTX) announced the appointment of Christopher Mitton as President of its subsidiary, Pearsanta Inc. Mitton brings over 20 years of leadership experience in medical diagnostics, focusing on personalized healthcare and molecular oncology. Pearsanta specializes in developing diagnostic tests for cancer, cardiology, immunology, gut health, and chronic conditions using proprietary platforms like Mitomic® Technology and AditxtScore™.
Under Mitton's leadership, Pearsanta aims to complete clinical validation studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™), with plans for commercial launch as laboratory developed tests. The company is also finalizing validation for the Mitomic® Ovarian Test (MOT™). Pearsanta's strategy includes leveraging existing partnerships and internal synergies within Aditxt to drive revenue and accelerate test adoption globally.
Aditxt Inc. (NASDAQ: ADTX) ha annunciato la nomina di Christopher Mitton a Presidente della sua filiale, Pearsanta Inc. Mitton porta con sé oltre 20 anni di esperienza nella leadership nel campo della diagnostica medica, concentrandosi sulla salute personalizzata e sull'oncologia molecolare. Pearsanta si specializza nello sviluppo di test diagnostici per il cancro, la cardiologia, l'immunologia, la salute dell'intestino e le malattie croniche utilizzando piattaforme proprietarie come Mitomic® Technology e AditxtScore™.
Sotto la guida di Mitton, Pearsanta mira a completare gli studi di validazione clinica per il suo Mitomic® Endometriosis Test (MET™) e Mitomic® Prostate Test (MPT™), con piani per il lancio commerciale come test sviluppati in laboratorio. L'azienda sta inoltre finalizzando la validazione per il Mitomic® Ovarian Test (MOT™). La strategia di Pearsanta prevede di sfruttare le partnership esistenti e le sinergie interne all'interno di Aditxt per aumentare le entrate e accelerare l'adozione dei test a livello globale.
Aditxt Inc. (NASDAQ: ADTX) anunció el nombramiento de Christopher Mitton como Presidente de su subsidiaria, Pearsanta Inc. Mitton aporta más de 20 años de experiencia en liderazgo en diagnósticos médicos, centrado en la salud personalizada y la oncología molecular. Pearsanta se especializa en desarrollar pruebas diagnósticas para cáncer, cardiología, inmunología, salud intestinal y condiciones crónicas utilizando plataformas propietarias como Mitomic® Technology y AditxtScore™.
Bajo el liderazgo de Mitton, Pearsanta tiene como objetivo completar estudios de validación clínica para su Mitomic® Endometriosis Test (MET™) y Mitomic® Prostate Test (MPT™), con planes de lanzamiento comercial como pruebas desarrolladas en laboratorio. La empresa también está finalizando la validación para el Mitomic® Ovarian Test (MOT™). La estrategia de Pearsanta incluye aprovechar las asociaciones existentes y las sinergias internas dentro de Aditxt para impulsar los ingresos y acelerar la adopción de pruebas a nivel global.
Aditxt Inc. (NASDAQ: ADTX)는 자회사인 Pearsanta Inc.의 회장으로 Christopher Mitton을 임명했다고 발표했습니다. Mitton은 개인 맞춤형 의료 및 분자 종양학에 중점을 두고 의료 진단 분야에서 20년 이상의 리더십 경험을 보유하고 있습니다. Pearsanta는 Mitomic® Technology 및 AditxtScore™와 같은 독점 플랫폼을 사용하여 암, 심장학, 면역학, 장 건강 및 만성 질환에 대한 진단 테스트 개발을 전문으로 합니다.
Mitton의 리더십 아래 Pearsanta는 Mitomic® Endometriosis Test (MET™) 및 Mitomic® Prostate Test (MPT™)의 임상 검증 연구를 완료하고, 실험실 개발 테스트로 상용화할 계획입니다. 회사는 또한 Mitomic® Ovarian Test (MOT™)의 검증을 마무리 중입니다. Pearsanta의 전략은 기존 파트너십과 Aditxt 내의 내부 시너지를 활용하여 수익을 증대하고 글로벌 테스트 채택을 가속화하는 것입니다.
Aditxt Inc. (NASDAQ: ADTX) a annoncé la nomination de Christopher Mitton en tant que Président de sa filiale, Pearsanta Inc. Mitton a plus de 20 ans d'expérience en leadership dans le domaine du diagnostic médical, en se concentrant sur la santé personnalisée et l'oncologie moléculaire. Pearsanta se spécialise dans le développement de tests diagnostiques pour le cancer, la cardiologie, l'immunologie, la santé intestinale et les maladies chroniques en utilisant des plateformes propriétaires telles que Mitomic® Technology et AditxtScore™.
Sous la direction de Mitton, Pearsanta vise à compléter des études de validation clinique pour son Mitomic® Endometriosis Test (MET™) et Mitomic® Prostate Test (MPT™), avec des plans pour un lancement commercial en tant que tests développés en laboratoire. L'entreprise finalise également la validation du Mitomic® Ovarian Test (MOT™). La stratégie de Pearsanta comprend l'exploitation des partenariats existants et des synergies internes au sein d'Aditxt pour générer des revenus et accélérer l'adoption des tests à l'échelle mondiale.
Aditxt Inc. (NASDAQ: ADTX) gab die Ernennung von Christopher Mitton zum Präsidenten ihrer Tochtergesellschaft Pearsanta Inc. bekannt. Mitton bringt mehr als 20 Jahre Führungserfahrung im medizinischen Diagnostikbereich mit, wobei der Fokus auf personalisierter Gesundheit und molekularer Onkologie liegt. Pearsanta hat sich auf die Entwicklung diagnostischer Tests für Krebs, Kardiologie, Immunologie, Darmgesundheit und chronische Erkrankungen spezialisiert, wobei proprietäre Plattformen wie Mitomic® Technology und AditxtScore™ verwendet werden.
Unter Mittons Führung beabsichtigt Pearsanta, klinische Validierungsstudien für seinen Mitomic® Endometriosis Test (MET™) und Mitomic® Prostate Test (MPT™) abzuschließen, mit Plänen für die kommerzielle Einführung als im Labor entwickelte Tests. Das Unternehmen finalisiert auch die Validierung für den Mitomic® Ovarian Test (MOT™). Die Strategie von Pearsanta umfasst die Nutzung bestehender Partnerschaften und interner Synergien innerhalb von Aditxt, um die Einnahmen zu steigern und die Einführung der Tests weltweit zu beschleunigen.
- Appointment of Christopher Mitton as President, bringing 20+ years of leadership in medical diagnostics
- Pearsanta nearing completion of clinical validation studies for Mitomic® Endometriosis and Prostate Tests
- Plans for commercial launch of tests as laboratory developed tests (LDTs)
- Potential for global expansion and partnerships to launch products outside the U.S.
- Addressing significant market needs in endometriosis, ovarian cancer, and prostate cancer diagnostics
- Closing of Appili Therapeutics and Evofem Biosciences transactions subject to various conditions, including shareholder approval and sufficient capital raising
- No assurance provided that all conditions for closing transactions will be met or that transactions will ultimately close
Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as Chief Executive Officer of MDNA Life Sciences, Inc.; before this, he headed sales operations at Cancer Genetics Inc., a commercial lab specializing in oncology. He led the North American commercial expansion for Ipsogen, a French molecular diagnostics company. Following Ipsogen’s acquisition by Qiagen, he managed Qiagen's entire personalized healthcare portfolio, driving significant advancements in precision diagnostics. Earlier in his career, Mr. Mitton held key sales positions with BioChem Immunosystems, Abbott Diagnostics, and Bayer Healthcare. He earned his B.S. in Molecular Biology from Florida A&M University.
Pearsanta, a majority owned Aditxt subsidiary, focuses on precision health. It specializes in developing diagnostic tests that address critical health challenges, particularly in cancer, cardiology, immunology, gut health and chronic conditions. Pearsanta’s proprietary platforms, Mitomic® Technology, and AditxtScore™, are dedicated to early disease detection and personalized treatment strategies. By advancing innovations in diagnostic technologies, Pearsanta aims to empower patients and healthcare providers to make more informed, personalized healthcare decisions.
Pearsanta is at the forefront of transforming disease detection and management through its innovative technologies. Central to this effort is the proprietary Mitomic® Technology Platform, which harnesses the unique properties of mitochondrial DNA (mtDNA) to identify specific mutations linked to various diseases through non-invasive, blood-based liquid biopsies. With its high mutation rate and persistence in cells, mtDNA serves as a unique biosensor suited for early disease detection, enabling the rapid and accurate identification of disease-associated biomarkers. The Mitomic® Technology Platform supports a robust biomarker portfolio that addresses numerous high-priority health concerns, including prostate, ovarian, and lung cancers and non-cancerous conditions like endometriosis.
In addition, Pearsanta is advancing the AditxtScore™ Technology Platform, which provides comprehensive immune system profiling. This platform allows for the monitoring of immune responses to various agents, including viruses, bacteria, and transplanted organs, as well as responses to therapeutic interventions. Together, these technologies position Pearsanta to transform the diagnosis and management of diseases, set new standards in precision healthcare, and significantly improve patient outcomes across a broad spectrum of medical conditions.
Under Christopher Mitton’s leadership, Pearsanta will prepare for its strategic commercial rollout. Pearsanta is seeking to complete clinical validation studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™), with a commercial launch planned as laboratory developed tests (LDTs) validated in Pearsanta’s CLIA CAP-certified lab in
Pearsanta’s go-to-market strategy will seek to leverage existing partnerships and capitalize on internal synergies within the Aditxt platform to drive revenue potential and accelerate test adoption. Aditxt is seeking to position Pearsanta for global expansion, with potential channel partners to launch Pearsanta’s products outside the
Pearsanta envisions a seismic shift in the global landscape of disease detection and diagnosis underpinned by advancements in precision medicine, including liquid biopsy technologies. As highlighted by Fortune Business Inside, the liquid biopsy sector is poised for exponential growth and is expected to surge from
"We believe that Pearsanta is at the forefront of personalized health, developing diagnostic innovations that have the potential to improve patient care significantly," said Christopher Mitton. "I’m eager to step into this role and lead the talented teams at Pearsanta as we work to redefine what's possible in precision health and deliver transformative outcomes for our patients."
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, "We are thrilled to welcome Chris to Pearsanta at this pivotal moment. Our mission at Aditxt is to build and accelerate companies focusing on innovative health solutions that tackle some of the most critical challenges in healthcare. We believe that Chris’s leadership will be key as we seek to drive the commercial success of Pearsanta, advancing breakthrough innovations and creating value for all stakeholders. We feel strongly that his personalized healthcare and commercial strategy expertise make him the ideal leader to guide Pearsanta's next growth phase as we accelerate our precision health initiatives."
Aditxt currently operates two programs focused on immune health and precision health. Following the completion of the Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) and Evofem Biosciences, Inc. (OTCQB: EVFM) transactions, Aditxt will introduce two additional programs dedicated to public health and women's health. Each program is designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of these transactions is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to discovering, developing, and deploying promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.
Aditxt has a diverse innovation portfolio, including Adimune™, Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity, and allergies. Adivir™, Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta™, Inc., delivers rapid, personalized, and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in
For more information, visit http://www.aditxt.com/.
Follow us on:
Linkedin: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute on its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partners to commence clinical trials and clinical validation studies; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in the Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826381655/en/
Mary O’ Brien
mobrien@aditxt.com
(516) 753-9933
Source: Aditxt, Inc.
FAQ
Who is the new President of Pearsanta, Aditxt's subsidiary?
What are the main diagnostic tests Pearsanta is developing?
What is the expected market size for liquid biopsy by 2030?
How many new cases of prostate cancer were anticipated in the US for 2023?
What is Aditxt's stock symbol?
